JP2001505226A - 副腎皮質刺激ホルモン放出因子(crf)アンタゴニスト活性を有するキノリンおよびキナゾリン誘導体 - Google Patents
副腎皮質刺激ホルモン放出因子(crf)アンタゴニスト活性を有するキノリンおよびキナゾリン誘導体Info
- Publication number
- JP2001505226A JP2001505226A JP51510099A JP51510099A JP2001505226A JP 2001505226 A JP2001505226 A JP 2001505226A JP 51510099 A JP51510099 A JP 51510099A JP 51510099 A JP51510099 A JP 51510099A JP 2001505226 A JP2001505226 A JP 2001505226A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- compound
- substituted
- mono
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.式I 式中、 −AはCHもしくはNであり、 −環Qは、場合によっては1もしくは2個の基R4で置換されたフェニル、ピリ ジル、ピリミジニルもしくはピリダジニルであり、 −環Yはフェニル、ピリジル、ピリミジニル、ピリダジニルもしくはピラジニル であり、 −R1およびR2は、場合によっては分枝状のC1-6アルキル、C3-6アルケニル 、C3-6アルキニル、C3-6シクロアルキル−C1-4アルキル、フェニル−C1-4ァ ルキル、5もしくは6員の飽和もしくは不飽和のヘテロシクリル−C1-4アルキ ルであり、この基R1およびR2は、OH、C1-3アルコキシ、C1-3アルコキシ カルボニル、場合によってはモノもしくはジ(C1-3アルキル)置換されたアミ ノ、ハロゲンまたはシアノで置換されることができ、 −R3はH、場合によっては1個もしくはそれ以上のフッ素原子で置換されたC1-3 アルキルであるか、または、R3はハロゲン、メトキシもしくはエトキシで あり、 −R4は、場合によっては1個もしくはそれ以上のフッ素原子で置換されたC1- 3 アルキルであるか、あるいは、R4はハロゲン、メトキシ、 エトキシ、アミノ、モノもしくはジ置換アミノまたはシアノであり、 −R5は、ハロゲン、場合によっては分枝状のC1-6アルキル、C3-6アルケニル 、C3-6アルキニル、C3-6シクロアルキル−C1-4アルキル、O−(C1-6アルキ ル)、S−(C1-6アルキル)、SO2−(C1-6アルキル)、ヒドロキシ、シア ノ、ニトロ、トリフルオロメチル、SO2NH2、SO2N(モノもしくはジC1-4 アルキル)、ホルミル、CO−(C1-6アルキル)、COOH、COO−(C1-6 アルキル)、CONH2、CON(モノもしくはジC1-4アルキル)、アミノ、N (モノもしくはジC1-4アルキル)、NHCO(C1-6アルキル)、NHSO2− (C1-6アルキル)であり、この基R5は同一もしくは異なることができ、そし て −nは値0ないし4を有するが、 ただし、基NR1R2はジエチルアミノ、エチル、n−プロピルアミノもしくはエ チル、n−ブチルアミノでなく、AがCHである場合にはQは未置換のフェニル であり、R3はメチルであり、そして基(1個もしくは複数)R5をもつ置換基Y は2,4,6−トリメチルフェニルである、 を有する化合物、およびその塩。 2.a)式II 式中、R3およびQは請求の範囲1で示された意味を有し、また、Xはいわゆる 脱離基である、 を有する化合物を、式Y’−B(OH)2(式中Y’はR5および(R 5)nで置換されたYと同一の意味を有し、そしてY、R5およびnは請求の範 囲1で示された意味を有する)のホウ素酸誘導体と反応させるか、または、b) 臭素誘導体(II)の代わりに、対応するホウ素酸誘導体を式Y’−Brの化合物 と反応させ、そして得られた化合物(III)を、a)式HNR1R2のアミンもしくはb)式R1−NH2のアミンを用い、次い で化合物R2−Cl、R2−BrもしくはR2−Iでのアルキル化で、式IV を有する化合物に転化することを特徴とする、AがCHである請求の範囲1に記 載された化合物の製造方法。 3.式III 式中、R3、Q、R5、Yおよびnは請求の範囲1で示された意味を有し、 そしてXはClもしくは場合によっては置換されたフェノキシ基である、 を有する化合物。 4.a)式VI 式中、R1〜R3およびQは請求の範囲1で示された意味を有する、 を有する化合物を、式Y’−B(OH)2のホウ素酸誘導体と反応させること、 または、b)臭素誘導体(VI)の代わりに、対応するホウ素酸誘導体を式Y’−B r(式中、式Y’は請求の範囲2で与えられた意味を有する)の化合物と反応さ せ、式VII を有する化合物を与えることを特徴とする、Aが窒素である請求の範囲1に記載 された化合物の製造方法。 5.有効成分として請求の範囲1に記載された最低1種の化合物を含有する製薬 学的組成物。 6.請求の範囲1に記載された最低1種の化合物の有効量を投与に適する形態に することを特徴とする、製薬学的組成物の製造方法。 7.請求の範囲5に記載された組成物が使用されることを特徴とする、ストレス に関連した現象に対する生理学的応答を弱める方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97202762 | 1997-09-09 | ||
EP97202762.7 | 1997-09-09 | ||
PCT/EP1998/005726 WO1999012908A1 (en) | 1997-09-09 | 1998-09-07 | Quinoline and quinazoline derivatives having corticotropin releasing factor (crf) antagonist activity |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001505226A true JP2001505226A (ja) | 2001-04-17 |
JP4276703B2 JP4276703B2 (ja) | 2009-06-10 |
Family
ID=8228716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51510099A Expired - Fee Related JP4276703B2 (ja) | 1997-09-09 | 1998-09-07 | 副腎皮質刺激ホルモン放出因子(crf)アンタゴニスト活性を有するキノリンおよびキナゾリン誘導体 |
Country Status (9)
Country | Link |
---|---|
US (1) | US6350750B1 (ja) |
EP (1) | EP0966442B1 (ja) |
JP (1) | JP4276703B2 (ja) |
AT (1) | ATE348812T1 (ja) |
AU (1) | AU9624198A (ja) |
CA (1) | CA2270777C (ja) |
DE (1) | DE69836678T2 (ja) |
NL (1) | NL1010018C2 (ja) |
WO (1) | WO1999012908A1 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0977737T3 (da) * | 1997-04-22 | 2004-01-26 | Janssen Pharmaceutica Nv | CRF-antagonistisk quino- og quinazoline |
US6432989B1 (en) | 1999-08-27 | 2002-08-13 | Pfizer Inc | Use of CRF antagonists to treat circadian rhythm disorders |
PL354784A1 (en) | 1999-09-30 | 2004-02-23 | Neurogen Corporation | Certain alkylene diamine-substituted heterocycles |
AU2001234180A1 (en) * | 2000-02-25 | 2001-09-03 | Japan Tobacco Inc. | Benzamide derivative and use thereof |
US6670362B2 (en) | 2000-09-20 | 2003-12-30 | Pfizer Inc. | Pyridazine endothelin antagonists |
PL377847A1 (pl) | 2003-01-14 | 2006-02-20 | Arena Pharmaceuticals Inc. | 1,2,3-Tripodstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie związanych z nim zaburzeń takich jak cukrzyca i hiperglikemia |
EA010023B1 (ru) * | 2003-07-14 | 2008-06-30 | Арена Фармасьютикалз, Инк. | Конденсированные арильные и гетероарильные производные в качестве модуляторов метаболизма и для профилактики и лечения расстройств, связанных с нарушением метаболизма |
CA2535249A1 (en) * | 2003-08-12 | 2005-02-17 | F. Hoffmann-La Roche Ag | Spiro-substituted tetrahydroquinazolines as corticotropin releasing factor (cfr) antagonists |
CA2534785A1 (en) * | 2003-08-12 | 2005-02-17 | Robin Douglas Clark | Tetrahydroquinazoline derivatives as cfr antagonists |
EP3378854B1 (en) | 2010-01-27 | 2022-12-21 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
BR112013008100A2 (pt) | 2010-09-22 | 2016-08-09 | Arena Pharm Inc | "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles." |
AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
SI3310760T1 (sl) | 2015-06-22 | 2023-02-28 | Arena Pharmaceuticals, Inc. | Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1 |
KR20190116416A (ko) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법 |
EP3601267A1 (en) | 2017-03-21 | 2020-02-05 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
EP3781565A1 (en) | 2018-04-18 | 2021-02-24 | Bayer Pharma Aktiengesellschaft | 2-methyl-aza-quinazolines |
US20230365563A1 (en) * | 2020-09-30 | 2023-11-16 | Shanghai Pharmaceuticals Holding Co., Ltd. | Quinazoline compound and application thereof |
TW202337890A (zh) * | 2021-04-30 | 2023-10-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 橋環類化合物、其製備方法及其在醫藥上的應用 |
CN115504932B (zh) * | 2022-08-12 | 2024-01-26 | 河南师范大学 | 一种3-取代喹啉类化合物的合成方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2891544B2 (ja) | 1994-06-16 | 1999-05-17 | ファイザー・インコーポレーテッド | ピラゾロおよびピロロピリジン類 |
TR199800792T2 (xx) * | 1996-02-07 | 1998-07-21 | Janssen Pharmaceutica N.V. | CRF resept�r antagonistleri olarak pirazolopirimidinler. |
TW477787B (en) * | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
WO1998029397A1 (fr) | 1996-12-27 | 1998-07-09 | Yoshitomi Pharmaceutical Industries, Ltd. | Composes pyrimidine a anneaux condenses et leur utilisation medicinale |
AU6279598A (en) * | 1997-02-18 | 1998-09-08 | Neurocrine Biosciences, Inc. | Biazacyclic CRF antagonists |
DK0977737T3 (da) * | 1997-04-22 | 2004-01-26 | Janssen Pharmaceutica Nv | CRF-antagonistisk quino- og quinazoline |
-
1998
- 1998-09-04 NL NL1010018A patent/NL1010018C2/nl not_active IP Right Cessation
- 1998-09-07 WO PCT/EP1998/005726 patent/WO1999012908A1/en active IP Right Grant
- 1998-09-07 AU AU96241/98A patent/AU9624198A/en not_active Abandoned
- 1998-09-07 AT AT98950008T patent/ATE348812T1/de not_active IP Right Cessation
- 1998-09-07 US US09/297,837 patent/US6350750B1/en not_active Expired - Lifetime
- 1998-09-07 JP JP51510099A patent/JP4276703B2/ja not_active Expired - Fee Related
- 1998-09-07 DE DE69836678T patent/DE69836678T2/de not_active Expired - Lifetime
- 1998-09-07 CA CA002270777A patent/CA2270777C/en not_active Expired - Fee Related
- 1998-09-07 EP EP98950008A patent/EP0966442B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2270777A1 (en) | 1999-03-18 |
EP0966442A1 (en) | 1999-12-29 |
US6350750B1 (en) | 2002-02-26 |
NL1010018C2 (nl) | 1999-03-10 |
WO1999012908A1 (en) | 1999-03-18 |
ATE348812T1 (de) | 2007-01-15 |
DE69836678T2 (de) | 2007-04-05 |
DE69836678D1 (de) | 2007-02-01 |
JP4276703B2 (ja) | 2009-06-10 |
CA2270777C (en) | 2008-04-22 |
EP0966442B1 (en) | 2006-12-20 |
AU9624198A (en) | 1999-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001505226A (ja) | 副腎皮質刺激ホルモン放出因子(crf)アンタゴニスト活性を有するキノリンおよびキナゾリン誘導体 | |
KR100256707B1 (ko) | 데아자푸린 유도체; 새로운 부류의 crf1 특이 리간드 | |
JP4086663B2 (ja) | 新規なスピロ三環式誘導体及びホスホジエステラーゼ7阻害剤としてのそれらの使用 | |
CN1315809C (zh) | 喹啉衍生物和其作为5-ht6配体的用途 | |
KR880002232B1 (ko) | 퀴놀린 유도체와 그 염의 제조방법 | |
JP4685243B2 (ja) | ピリミド[6,1−a]イソキノリン−4−オン誘導体 | |
JP2000512995A (ja) | イミダゾキノリンアミン調製方法 | |
MX2009002069A (es) | Sintesis de 2-(piridin-2-ilamino)pirido[2,3-d]pirimidin-7-onas. | |
WO1992007830A2 (en) | Oxindole peptide antagonists | |
JPH0232058A (ja) | 4―アミノ―3―カルボキシキノリン類およびナフチリジン類、製法および医薬用途 | |
TWI781607B (zh) | 一種免疫抑制劑、其製備方法和應用 | |
AU745051B2 (en) | Benzothiadiazoles and derivatives | |
US5665733A (en) | 3-phenylisoquinol-1(2H)-one derivatives their preparation and their therapeutic application | |
JP2002507613A (ja) | ピペリジン誘導体 | |
JP2007507514A (ja) | キノキサリン化合物 | |
JPS6036486A (ja) | 新規イミダゾール | |
JPS59167592A (ja) | 含窒素複素環で置換されたトリアゾロ〔4,3−c〕ピリミジンおよびトリアゾロ〔1,5−c〕ピリミジン | |
JPH06763B2 (ja) | ベンゾ〔h〕シンノリン誘導体 | |
JPS6365672B2 (ja) | ||
JPS60197687A (ja) | インドロフエナントリジン類 | |
WO2000040565A1 (en) | Tetrahydroindazole derivatives as ligands for gaba-a alpha 5 receptors | |
KR880001719B1 (ko) | 1,4,9,10-테트라하이드로-피라졸로[4,3-e]-피리도[3,2-b][1,4]디아제핀-10-온의 제조 방법 | |
EA005071B1 (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[4,3-e]ДИАЗЕПИНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ИХ, И ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ ПРОДУКТОВ | |
JPH0859655A (ja) | 2,3−ジヒドロ−1h−イソインドール誘導体、それらの製法およびセロトニン再取込み阻害剤としてのそれらの使用 | |
JPH05247052A (ja) | N−アルキルグルタールイミドの4−(4−ピペリジニル)−チエノ〔3,2−c〕ピリジン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040928 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080520 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080612 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080820 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080929 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081114 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090303 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090309 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120313 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |